Pharmaceuticals & Therapeutics

Adial Pharmaceuticals appoints the architect behind the first FDA-approved AhR agonist to lead its new ulcerative colitis drug into 2027 clinical trials.

As Jasper Therapeutics completes Phase 2 enrollment for its novel IgAN therapy, we examine the structural shifts reshaping rare kidney disease treatment.

LTR Pharma’s Roxus nasal spray promises ED treatment in ten minutes. But the real disruption is how the company is using compounding laws to enter the U.S. market.

Merz completes Phase III migraine trial recruitment six months early, signaling a strategic threat to AbbVie’s dominance with its purified neurotoxin, XEOMIN.

By halving infusion volumes for immunodeficiency patients, Takeda's experimental TAK-881 is not just treating a disease—it is giving people their time back.

By out-licensing its early-stage hypophosphatasia drug, 1cBio secured non-dilutive capital to fund its proprietary oncology pipeline without the usual risks.

The clinical-stage biotech's public debut tests investor appetite for immunology as it funds a novel Treg pipeline into 2029.

As a new foundation offers free seminars for Thyroid Eye Disease, it highlights the complex intersection of rare disease advocacy and pharmaceutical marketing.

As Medicare ramps up scrutiny on skin substitutes, a new zero-upfront-cost biologic program promises clinical results and protection from financial ruin.

As the National Academy of Medicine's $1.5M competition concludes, a novel biologic targeting muscle loss challenges how we treat human aging.

Trevi Therapeutics heads to CHEST 2026 with compelling patient-reported outcomes for its IPF chronic cough drug, aiming to fill a massive clinical void.

By proving IBSRELA reduces costly specialist visits, Ardelyx is arming itself for payer negotiations and a lucrative leap into the broader constipation market.

Phathom Pharmaceuticals is using predictive modeling to prove its premium-priced drug VOQUEZNA can beat generic PPIs by preventing long-term complications.

NurExone Biologic reports statistically significant preclinical data for its exosome therapy, taking a crucial step toward reversing optic nerve damage.

For decades, severe acne treatments forced patients into a maze of antibiotics and harsh side effects. A new drug might finally change the system.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

Boehringer Ingelheim’s new quarterable PREVICOX tablets offer precise dosing for small dogs and slash supply chain waste, proving small tweaks yield big gains.

Oncodesign Precision Medicine is advancing its LRRK2 inhibitor OPM-201 toward Phase 1b. Here is how strategic repatriation and non-dilutive funding are paving the commercial pathway.

The Food Allergy Science Initiative is shifting from basic research to biotech incubator, launching a $10M accelerator to turn academic discoveries into drugs.

AmyriAD Therapeutics is betting an all-stock deal can turn a missed Phase 2b endpoint into a breakthrough for cognitive impairment in schizophrenia.